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Abstract
Introduction Emerging evidence points to an association between severe clinical presentation of COVID-19 and increased risk of
thromboembolism. One-third of patients hospitalized due to severe COVID-19 develops macrovascular thrombotic complica-
tions, including venous thromboembolism, myocardial injury/infarction and stroke. Concurrently, the autopsy series indicate
multiorgan damage pattern consistent with microvascular injury.
Prophylaxis, diagnosis and treatment COVID-19 associated coagulopathy has distinct features, including markedly elevated D-
dimers concentration with nearly normal activated partial thromboplastin time, prothrombin time and platelet count. The diag-
nosis may be challenging due to overlapping features between pulmonary embolism and severe COVID-19 disease, such as
dyspnoea, high concentration of D-dimers, right ventricle with dysfunction or enlargement, and acute respiratory distress
syndrome. Both macro- and microvascular complications are associated with an increased risk of in-hospital mortality.
Therefore, early recognition of coagulation abnormalities among hospitalized COVID-19 patients are critical measures to
identify patients with poor prognosis, guide antithrombotic prophylaxis or treatment, and improve patients’ clinical outcomes.
Recommendations for clinicians Most of the guidelines and consensus documents published on behalf of professional societies
focused on thrombosis and hemostasis advocate the use of anticoagulants in all patients hospitalized with COVID-19, as well as
2-6 weeks post hospital discharge in the absence of contraindications. However, since there is no guidance for deciding the
intensity and duration of anticoagulation, the decision-making process should be made in individual-case basis.
Conclusions Here, we review the mechanistic relationships between inflammation and thrombosis, discuss the macrovascular
and microvascular complications and summarize the prophylaxis, diagnosis and treatment of thromboembolism in patients
affected by COVID-19.
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Introduction
The severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), responsible for the coronavirus disease 2019
(COVID-19), originated in Wuhan, China, in December
2019. SARS-CoV-2 is a new ribonucleic acid (RNA) virus
strain from the Coronaviridae family, firstly described by
Zhou et al. in February 2020 [1]. In March 2020, COVID-19
was declared a pandemic by the World Health Organization
(WHO), involving at the end of May more than 100 countries
worldwide, number of cases and deaths rapidly increasing ev-
ery day. On 25th June 2020, the WHO’s 157th Situation
Report of COVID-19 announced that more than 9 million peo-
ple worldwide had been infected by this virus, which has
caused almost 480,000 deaths in barely 6 months. Europe
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Key Features
- There is a strong association between severe COVID-19 and thrombo-
embolism.
- COVID-19-associated coagulopathy has distinct features.
- Symptoms of severe COVID-19 disease and pulmonary embolism over-
lap.
- Early recognition of thrombotic complications is critical to improve
outcomes.
- Anticoagulation should be used in most patients hospitalized with
COVID-19.
- There is no consensus regarding the anticoagulation intensity and
duration.
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and America have been the most affected regions, accounting
for almost 80% of worldwide cases and deaths [2]. Despite
SARS-CoV-2 strains having a within-sequence identity of
99.98%, it has been classified in 2 haplogroups (A and B),
the first being the predominant worldwide and the second be-
ing more prevalent in America and Asia than in Africa and
Europe [3]. Nevertheless, it remains unclear whether the sever-
ity and outcome of the disease are related to the virus strain.
SARS-CoV-2 fundamentally uses the angiotensin-
converting enzyme 2 (ACE2) receptor to enter the cell through
the binding with spike-like protein (S protein), although other
cell receptors may be alternatively bound. In addition, ACE2
plays a major role in viral proliferation [4]. ACE2 is widely
expressed in different organs and tissues, which concurs with
the panoply of clinical systemic symptoms and multiorgan
dysfunction presented with COVID-19, such as respiratory,
renal, hepatic, gastrointestinal, and cardiac damage [5]. Both
the down- and upregulation of ACE2 appear to play a major
role in heart failure, hypertension, myocardial infarction, and
overall cardiovascular disease (CVD) [6]. On those grounds, it
is not surprising that patients with underlying CVD have 1.7-
fold higher mortality rate caused by COVID-19 than patients
with chronic respiratory disease, despite the respiratory sys-
tem being the principal target of the virus [7].
Emerging evidence points to a strong association between
severe clinical presentation of COVID-19 and increased risk
of thromboembolism, although the mechanisms behind this
are not completely understood [8]. Several risk factors have
been described for such an association, such as systemic
hyperinflammation driven by the coronavirus infection, hyp-
oxia, and comorbidities associated with hospitalization of crit-
ical patients [9]. Whence, understanding the clinical and
mechanistic features of COVID-19 severity and mortality is
critical to identify and treat patients at the highest thromboem-
bolic risk and mortality. We aim to review the mechanistic
relationships between inflammation and thrombosis, discuss
the macrovascular andmicrovascular complications, and sum-
marize the diagnosis, prophylaxis, and treatment of thrombo-
embolism in patients affected by COVID-19.
Mechanistic Relationships
Between Inflammation and Thrombosis
Pathophysiology of Thrombosis
The thrombotic response involves activation of platelets and
the coagulation cascade [10]. Remembering Virchow’s triad,
changes in the blood flow, constituents, or vessel wall can
precipitate thrombosis [11]. Platelet activation is initiated by
several agonists, including collagen via glycoprotein (GP) VI
receptors and thrombin via protease-activated receptors
(PAR) 1 and 4. Upon activation, several key processes occur.
First, arachidonic acid is converted to thromboxane A2, a po-
tent pro-aggregatory and vasoconstrictive factor [12]. Second,
platelets degranulate. Dense granules, containing adenosine
diphosphate (ADP), fuse with the cell membrane [13]. ADP
then acts on platelet P2Y1 and, most importantly, P2Y12 re-
ceptors, further stimulating and amplifying platelet activation
[14]. Similarly, alpha granules, containing P-selectin as
well as other proinflammatory and procoagulant factors,
fuse with the membrane. P-selectin binds to a range on
inflammatory cells, including neutrophils and monocytes
[15]. Thirdly, through calcium mobilization and dephos-
phorylation of vasodilator-stimulated phosphoprotein
(VASP), platelets undergo shape change from discoid to
stellate forms, meaning physical aggregation occurs [16].
Conformational change in the GP IIb/IIIa receptor, which
forms cross-links with other GP IIb/IIIa, strengthening
platelet-platelet binding, and also stimulating other plate-
lets to activate via outside-in signalling [17]. In addition,
platelets and vascular and blood cell also release extracel-
lular vesicles by outward blebbing, which are small parti-
cles released by almost all cell types when activated or
injured, and composed by multiple bioactive molecules
such as RNA, miRNA, cytokines, transcription and growth
factors, and even small amounts of DNA, and lipids (they
are rich in phospholipids) because they are enveloped in a
lipid bilayer cell-derived membrane [18, 19]. Some extra-
cellular vesicles expose phosphatidylserine in their external
layer and therefore elicit a 50- to 100-fold higher procoagulant
activity than activated platelets [20].
In addition to platelets and extracellular vesicles, activation
of the coagulation cascade plays an important role in throm-
bosis [21]. Broadly divided into two converging pathways,
activation of the extrinsic pathway by tissue factor and/or
contact activation of the intrinsic pathway, coagulation cas-
cade leads to activation of factor X, a constituent of the
prothrombinase complex, resulting in thrombin generation.
Thrombin cleaves soluble fibrinogen to insoluble fibrin,
which forms interweaving strands, further stabilized by factor
XIII. There is interplay between the coagulation cascade and
platelets. Not only can thrombin activate platelets through
PAR1 and PAR4, but also conversely platelets themselves
can catalyze thrombin generation via membrane scramblase
activity [22].
Although there is considerable overlap between platelet-
and coagulation-mediated effects, the prominent mechanism
of initiation varies by setting. Platelet activation is typically
most prominent, whereas, [23] whereas in the venous circula-
tion activation of the coagulation cascade predominates [24].
The Inflammatory Response
The inflammatory response includes a complex network of
factors, triggered by insults such as infection, trauma, or
Cardiovasc Drugs Ther
toxicity. Broadly, this is initiated by damage pattern recogni-
tion receptors found on a range of leukocytes [25]. This leads
to recruitment and translocation of other leukocytes, release of
cytokines and other inflammatory mediators, activation of
complement, and physical attack of pathogens or infected
cells [26]. Specifically in COVID-19-associated systemic in-
flammation, severe disease is associated with increased levels
of cytokines such as interleukin (IL)-6, tumor necrosis factor
(TNF)-α, and IL-2R [27]. Levels of, for example, IL-6 have
also been associated with outcomes in severe COVID-19 [28].
Role of Platelets During Inflammation
Platelets too play an important role in the regulation and en-
actment of the inflammatory response. Acute inflammation,
for example, during endotoxemia, is associated with increased
number of platelet-monocyte and platelet-neutrophil aggre-
gates, mediated via enhanced P-selectin expression.
Inhibiting platelets with P2Y12 inhibitors in this setting leads
to in lower detectable plasma levels of cytokines such as IL-6
and TNF-α [29, 30].
Platelet reactivity, measured by numerous assays, is in-
creased during acute inflammatory states, for example, sepsis
[31]. Platelets themselves are acute phase reactants and in-
flammation induces thrombocytosis, mediated by an increase
in thrombopoetin levels, potentiated by interleukin-6 [32].
Moreover, markers correlating closely with thrombotic risk,
such as mean platelet volume and immature platelet fraction,
or increased levels of circulating extracellular vesicles derived
from platelets and leukocytes are increased during acute in-
flammation [33–35]. Raised circulating levels during inflam-
mation of other platelet agonists such as adrenaline, via α2
receptors and serotonin (5-HT), via 5-HT2A receptors, may
also contribute to enhanced reactivity [36, 37].
Role of Acellular Coagulation During Inflammation
Acute inflammation, triggered by a virus infection, for in-
stance, is also associated with prothrombotic changes in fibrin
clot dynamics, including increased fibrin strand density and
clot turbidity [29]. Similarly, levels of markers such as D-
dimer and fibrinogen may be elevated. Thrombin generation,
which is increased during inflammation [38], drives not only
coagulation and platelet activation but also inflammationmore
directly through promotion of leukocyte recruitment [39].
Conversely, severe inflammation can lead to such an increase
in prothrombotic tendency that widespread microvascular
thrombosis occurs, known as disseminated intravascular co-
agulation. This results in a fall in detectable clotting factors as
these are consumed rapidly, and can paradoxically lead to
reduced hemostatic function and therefore increased bleeding
risk [40].
Effect of Inflammation on the Endothelium
Endothelial function is adversely affected during systemic in-
flammation. In particular, the release of vonWillebrand factor
(vWF) is increased, which facilitates platelet-endothelium and
platelet-platelet binding, On the contrary in the activity of the
antithrombotic factors tissue factor pathway inhibitor and pro-
tein C are reduced[41]. In the arterial circulation, inflamma-
tion can also drive atheromatous plaque progression,
impacting on local hemodynamics and also on plaque stabil-
ity, making plaque rupture or erosion events, which can trig-
ger thrombosis, more likely [42].
Macrovascular Complications
One-third of patients hospitalized due to severe COVID-19
develop macrovascular thrombotic complications which are
associated with an increased risk of in-hospital mortality [43,
44]. These complications include especially venous thrombo-
embolism (VTE), and also stroke and acute myocardial
infarction.
Venous Thromboembolism
Elevated D-dimer concentration and thrombotic microangiop-
athy in pulmonary vessels on autopsy have raised the concern
of pulmonary embolism (PE) as a reason of acute respiratory
failure in patients with COVID-19. The in-hospital incidence
of acute PE differs among studies, with the highest rate in
severely ill patients admitted to intensive care unit (ICU)
[45–56]. In a case series of 12 patients with severe COVID-
19, post-mortem autopsies showed that VTE occurred in 7 of
12 (58%) patients, with PE being the direct cause of death in 4
of them (33%) [57]. To date, the largest published study in-
cluded 388 patients [45]. Of these, 16% patients were admit-
ted to the ICU. The cumulative rate of thromboembolic event
was 21%, rising from 7% of patients admitted to the general
ward to 28% of patients in the ICU. By pooling the data of all
the studies (1765 patients) reporting the frequency of VTE in
COVID-19, the overall incidence of VTEwas 21.9% [8]. This
cumulative incidence ranged from 31.3% in studies that in-
cluded more than 75% ICU patients to 8.6% in studies that
included less than 75% ICU patients. The high heterogeneity
observed between the studies reflects the discrepancies of the
inclusion criteria (e.g., patients with PE only vs. patients with
PE with/wi thout deep vein thrombosis [DVT]) ,
thromboprophylaxis strategies, and definition of outcomes.
This heterogeneity may lead to bias, highlighting the urgent
need for further high-quality prospective research.
Only a few studies have reported the anatomical location of
acute PE in COVID-19 patients [45, 47, 49, 58]. In a retro-
spective study of 137 patients with COVID-19, in which all
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patients underwent computed tomography pulmonary arteri-
ography (CTPA) of the pulmonary arteries, a total of 32 PE
were identified, of which ten were proximal PE, 18 involved
segmental pulmonary arteries, and the remaining four PEwere
multiple subsegmental pulmonary arteries [58]. The segmen-
tal and subsegmental location of PE was also the most com-
mon in other studies [45, 49, 53]. It should be noted that only
about one-third of COVID-19 patients undergo CTA during
the hospital stay [45, 49, 53]. The risk of infection for both
operators and other patients and the difficulties in performing
CTPA in mechanical ventilated patients in prone position are
the main reasons for the relatively low frequency of CTPA in
these patients. Consequently, it cannot be excluded that the
incidence of acute PE has been underestimated in patients
with COVID-19.
Current data on the incidence of DVT in patients with
COVID-19 are rather poor. In a recent study of 143 patients
with COVID-19 undergoing ultrasonography of the lower
limbs, DVT was found in 46.1% of patients [59]. Of these,
23 (34.8%) were proximal and 43 (65.2%) were distal DVTs.
The Padua prediction score of 4 or higher and a D-dimer
greater than 1.0 μg/ml were significantly associated with a
more than 4-fold increased risk of DVT. Noteworthy, among
distal vein thrombosis, 65% was in the intramuscular veins,
regardless of whether it was symptomatic or asymptomatic.
The clinical and prognostic meaning of asymptomatic distal
DVT in these patients remains to be determined.
Arterial Thrombosis
Both stroke and acute myocardial infarction have been de-
scribed in patients with COVID-19. In observational studies,
the proportion of COVID-19 patients with stroke ranges from
2.7 to 3.8% [45, 47, 48, 50, 53]. By pooling the available data
(973 patients), the overall prevalence of in-hospital acute
stroke is 3.5% (95% CI 2.4–4.8%), without statistical hetero-
geneity between the studies [8]. Both ischemic and hemor-
rhagic stroke can complicate the course of COVID-19. In a
series of 6 patients, 4 patients had an ischemic stroke and 2
patients a hemorrhagic stroke [60]. Acute stroke in patients
with COVID-19 is often associated with pre-existing cardio-
vascular risk factors and is a negative prognostic factor [61].
The mechanisms by which SARS-CoV-2 infection can trigger
stroke depend on the associated pathogen and host character-
istics. The presence of a prothrombotic state or a vasculitis-
like mechanism may partly explain this association [60].
Myocardial injury indicated by increased troponin level
may occur in 7–17% of COVID-19 patients admitted to the
general ward and in 22–31% of those admitted to the ICU [44,
62, 63]. In a recent meta-analysis of 8 studies from China
including 46,248 infected patients, 7% of patients experienced
myocardial injury (22% of the critically ill), as evidenced by
elevated cardiac troponin [64]. Noteworthy, patients with
myocardial injury had higher in-hospital mortality (37.5%)
than patients with cardiovascular disease (CVD) but without
myocardial injury (13.3%), or patients without CVD (7.6%).
Moreover, if myocardial injury was present in patients with
pre-existing CVD, the mortality increased even more (69.4%)
[65]. It was also demonstrated that myocardial injury is an
equivalent to previous myocardial infarction in terms of mor-
tality risk in COVID-19 patients [43]. Clearly, myocardial
injury and underlying CVD markedly deteriorate the progno-
sis in COVID-19. The possible mechanisms explaining this
association include (i) cytokine storm, (ii) microangiopathy,
(iii) viral myocarditis, (iv) stress-induced cardiomyopathy,
and (iv) classic myocardial infarction due to infection-
induced atherosclerotic plaque instability [66, 67].
The management of both acute ischemic stroke and acute
myocardial infarction can be challenging in these patients due
to the need of urgent reperfusion and frequent lack of standard
procedures to perform reperfusion in COVID-19 patients, es-
sential to ensure the best care of patients. The role of veno-
arterial extracorporeal membrane oxygenation (ECMO) as a
form of rescue therapy in the case of COVID-19-associated
cardiovascular collapse is currently under investigation.
Microvascular Complications
Microvascular thrombosis is defined as pathological occlusion
of microvessels (arterioles, capillaries, and venules) by
platelet- and/or fibrin-rich thrombi [68]. Classically, micro-
vascular thrombosis includes thrombotic microangiopathies
(e.g., thrombocytic thrombocytopenic purpura, hemolytic-
uremic syndrome) and disseminated intravascular coagulation
(DIC) [69]. Microvascular thrombosis is a diagnostic chal-
lenge, because (i) microthrombi are difficult to visualize due
to their small size (often ≤ 10 μm), (ii) microthrombi often
occur only transiently, and (iii) specific biomarkers to detect
them are lacking [68]. Clinically, microvessel occlusion leads
to ischemia, with the effects ranging from alterations in plas-
ma coagulation markers to severe multiorgan failure [70].
Although in most cases the evidence indicating a causal rela-
tionship between microvascular thrombosis and organ failure
is difficult to obtain, microvascular thrombosis appears to
have a critical importance in the course of COVID-19 [71].
Emerging evidence shows that severe COVID-19 can be
complicated with coagulopathy of a prothrombotic character
and is associated with poor prognosis [72]. Although many
patients with severe COVID-19 present with coagulation ab-
normalities that mimic thrombotic microangiopathy or DIC,
COVID-19-associated coagulopathy has distinct features
[73]. The first autopsy series of four patients who died due
to severe COVID-19 demonstrated a unique pathological pic-
ture, with the presence of diffuse microthrombosis and hem-
orrhage along with abundant intravascular megakaryocytes in
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all major organs, including the lungs, heart, kidneys, and liver
[74]. Since the gross pulmonary thromboembolism and paren-
chymal inflammation were absent, this picture has been de-
scribed as pauci-inflammatory thrombogenic vasculopathy.
Another autopsy series of five patients with COVID-19 and
acute respiratory distress syndrome (ARDS) demonstrated the
lung and skin damage consistent with complement-mediated
microvascular injury, whereas the hallmarks of classic ARDS
with diffuse alveolar damage and hyaline membranes were
not prominent [75]. The distinct respiratory distress syndrome
accompanying severe COVID-19 has been termed microvas-
c u l a r C OV I D - 1 9 l u n g v e s s e l s o b s t r u c t i v e
thromboinflammatory syndrome (MicroCLOTS) [76] or
lung-restricted vascular immunopathology [77].
The pathophysiological mechanisms underlying COVID-
19-associated coagulopathy are summarized in Fig. 1. These
mechanisms seem to follow Virchow’s triad, including (i)
diffuse endothelial cell injury, (ii) abnormal blood flow dy-
namics, and (iii) uncontrolled platelet activation [71]. SARS-
CoV-2 enters the target cells through the ACE2 receptors,
which are widely expressed on the surface of lung epithelial
cells, and arterial and venous endothelial cells in multiple
organs [78]. Virus infection causes direct endothelial injury,
dysfunction, and prothrombotic gene expression [79]. In ad-
dition to the direct effect, the virus triggers innate immune
responses, including the activation of monocytes and
complement cascade, responsible for a massive local release
of proinflammatory cytokines and aggravation of endothelial
i n j u r y and m i c r ova s cu l a r t h r ombos i s , t e rmed
immunothrombosis [76]. The major mediators of
immunothrombosis include tissue factor (TF) and neutrophils.
TF, exposed particularly by activated monocytes and
monocyte-derived extracellular vesicles, is a major initiator
of thrombosis in vivo [80]. Neutrophils, in turn, stabilize
microthrombi via the release of neutrophil extracellular traps
(NETs) and neutrophil elastase, which immobilize inflamma-
tory cells and promote intravascular fibrin formation via deg-
radation of TF antagonist, a tissue factor pathway inhibitor
[81].
Abnormal flow dynamics results from high blood concen-
trations of vWF, cell-free DNA, histones, and viral RNA in
course of COVID-19, which all cause factor XI activation,
thrombin generation, and intravascular fibrin formation, lead-
ing to change in blood flow rheology [82]. Platelet activation
is induced both indirectly by NETs and directly by virus in-
fection. NETs lead to platelet activation via toll-like receptors
on platelets and other cells, therefore integrating pulmonary
infection, inflammation, and thrombosis [83, 84]. There is
data showing that platelets and megakaryocytes may have
receptors for viruses [85–87] and could be infected by earlier
SARS-CoV [88]. Although currently there is no evidence of
direct infection of platelets or megakaryocytes by SARS-
Fig. 1 The pathophysiological
mechanisms underlying COVID-
19-associated coagulopathy.
These mechanisms seem to
follow Virchow’s triad, including
(i) diffuse endothelial cell injury,
(ii) abnormal blood flow
dynamics, and (iii) uncontrolled
platelet activation [71]
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CoV-2, the abundance of megakaryocytes in the lungs at au-
topsy seems to co-localize with platelet-rich thrombi [7].
Altogether, the immunothrombosis pathway in the lungs
might be a starting point for the systemic propagation of
COVID-19 infection, but more research is needed to elucidate
this process.
Altogether, the mechanisms underlying microvascular
thrombosis in course of COVID-19 may be related to diffuse
vascular endothelial cell injury, hyperimmune reaction of the
host, and maladaptive platelet aggregation. Clinician aware-
ness of microvascular thrombosis during COVID-19 infection
is crucial, since prompt recognition may be life-saving [89].
Diagnosis, Prophylaxis, and Treatment
of Thromboembolism
Thrombosis and thromboembolic complications in patients
hospitalized with COVID-19 should be assessed by integrat-
ing physical examination findings, patient history, results of
laboratory tests reflecting hemostasis, and/or results of fo-
cused imaging investigations. Patients who exhibit signs and
symptoms of DVT and have risk factors for thrombosis (pre-
vious thrombotic events, active malignancy, or current use of
hormonal therapy), unexplained and sudden deterioration in
respiratory status, and unexplained hypotension and/or tachy-
cardia should be further clinically evaluated to rule out throm-
botic complications. In patients with high suspicion of throm-
bosis, most readily available imaging studies such as bilateral
compression ultrasonography of the legs and/or bedside point-
of-care cardiac ultrasonography should be used to detect prox-
imal DVT, myocardial thrombus, clot-in-transit to the pulmo-
nary trunk or right ventricular dilatation [92–95]. However,
negative findings of these tests are insufficient to fully exclude
thrombosis [92–95]. If the underlying etiology of persisting
hemodynamic and respiratory compromise is not detected by
less complex imaging modalities, a CTPA should be under-
taken. On the other hand, a normal D-dimer test performed
with high-sensitivity assays in this population reasonably
rules out VTE, while positive D-dimer test does not confirm
thrombosis, and therefore, a further imaging workup is war-
ranted. Table 1
Importantly, elevations of laboratory parameters indicating
hypercoagulability at the admission of patients with COVID-
19 are associated with an increased incidence of in-hospital
thromboembolic events and mortality [44, 52, 72, 96–98]. For
example, in a recent report including 2377 consecutive adults
hospitalized with COVID-19, 76% of patients had elevated D-
dimer at presentation which had prognostic value for the se-
vere course of COVID-19 infection, including 2-fold higher
odds for critical illness, thrombotic events, acute kidney inju-
ry, and death. Importantly, the rates of adverse events in-
creased with the magnitude of D-dimer elevation [99]. The
initial prothrombotic cascade in patients with COVID-19 is
similar as in critical patients with DIC and consumptive coag-
ulopathy; however, there are clear differences between
COVID-19-associated coagulopathy and patients that have
classical DIC. Notably, coagulopathy in COVID-19 patients
is primarily characterized by the marked elevations in D-
dimer and fibrin/fibrinogen degradation product levels while
thrombocytopenia and prolongations of activated partial
thromboplastin time (aPTT) and/or prothrombin time (PT)
are less common or usually mild [100]. Accordingly, a
hyperfibrinolytic consumptive DIC with a bleeding diathesis
is a rare and unlikely event in these patients [100]. A worsen-
ing trend of coagulation parameters during an ICU stay gen-
erally indicates impending clinical deterioration, development
of cytokine storm, and progression tomultiorgan failure [101].
The procoagulant pattern in severe COVID-19 patients,
assessed by standard laboratory and viscoelastic tests, re-
vealed increased clot strength (CS), increased platelet and fi-
brinogen contribution to CS, elevated D-dimer levels, and
hyperfibrinogenemia [102]. Similarly, a complete lack of fi-
brinolysis of a clot at 30 min and exuberant increase in D-
dimer levels were strongly associated with thromboembolic
events and renal failure [97]. Furthermore, levels of C-reactive
protein (CRP), IL-6, factor VIII, vWF, and plasma viscosity
are increased in these patients while antithrombin is modestly
decreased thus clearly showing a cross-link between
infection-induced inflammatory response and thrombosis,
known as infection-induced thromboinflammation [100,
102–104]. A summary of the most important laboratory pa-
rameters reflecting hemostasis derangement in patients with
COVID-19 is shown in Table 2.
In terms of laboratory workup, measurements of D-dimer
levels, PT/aPTT, thrombocyte count, and fibrinogen levels (if
assays are available) are advised to identify hospitalized
COVID-19 patients at a high risk of poor in-hospital out-
comes, or to triage patients that would require hospital admis-
sion and close monitoring [105, 106]. Repeated assessments
(every 2–3 days) of D-dimer, PT, and the platelet count at the
minimum should be integrated into the diagnostic approach,
as recommended by the documents of relevant societies [73,
106]. PT expressed as an international normalized ratio (INR)
should not be used to monitor hemostasis in COVID-19 pa-
tients, since it mostly lies in the normal range. Early recogni-
tion and vigilant monitoring of coagulation abnormalities
among hospitalized COVID-19 patients are critical measures
to (i) identify patients at a high risk of poor prognosis, (ii)
guide antithrombotic prophylaxis or treatment to prevent
thromboembolic complications, and (iii) improve patients’
clinical outcomes.
Most of the guidelines and consensus documents published
on behalf of professional societies focused on thrombosis and
hemostasis advocate the use of prophylactic doses of antico-
agulants in all patients hospitalized with COVID-19 in the
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absence of contraindications [105–108]. Likewise, extended-
duration thromboprophylaxis with low molecular weight hep-
arin (LMWH) or a non-vitamin K antagonist oral anticoagu-
lants (NOAC) for 2 to 6 weeks post-hospital discharge might
be applied to hospitalized COVID-19 patients, especially
those with no bleeding risk factors and with high VTE risk
post-discharge (most commonly defined as advanced age,
long stay in the ICU, malignancy, prior VTE history,
thrombophilia, severe immobility, D-dimer levels > 2 times
of upper reference range, an IMPROVE VTE score ≥ 4, and
similar). Such recommendations are made due to observed
hypercoagulability and a robust number of studies that consis-
tently showed a high incidence of thromboembolic complica-
tions, especially venous thromboembolism in hospitalized and
particularly ICU-treated COVID-19 patients [45, 46, 48, 49,
52]. Likewise, most of the available documents support the
possibility to initiate intermediate-dose LMWH in selected
severe COVID-19 patients by individually balancing
Table 1 The summary of studies reporting the frequency of VTE complications in COVID-19 patients
Studies Study design No.
of pts
Setting Male Mean
age
Median
follow-
up
Rates of
PE during
follow-up
Incidence
of VTE
Use of thrombophophylaxis
Lodigiani et al. [45] R
Single center
388 ICU and
general
ward
58% 66 10 days 4.4% 21% Enoxaparin or nadroparin.
ICU, 100%; Ward, 75%.
Regimen not specified
Poissy et al. [46] R
Single center
107 ICU 59.1% 57 6 days 20.6% 20.4% 20 out of the 22 PE patients
were on prophylactic
LMWH or UFH, but
exact agents not specified.
Klok et al. [47, 48] R
Multicenter
184 ICU 76% 64 10 days 37% 57% Varied by center.
Middeldorp et al. [49] R
Single center
198 ICU and
general
ward
66% 61 5 days 17% 15% at 7
days
34% at 14
days
ICU: nadroparin 2850 IU
BID if weight < 100 kg,
and 5700 IU BID if
weight > 100 kg. Ward
patients had half this dose
Helms et al. [50] R
Multicenter
150 ICU 81% 63 NR 18% NR LMWH (exact agent not
specified) 4000 Units per
day or UFH 5–8 U/kg/h
Llitjos et al. [51] R
Double
center
26 ICU 77% 68 NR 23% NR LMWH and UFH were used
(exact agents not specified)
Thomas et al. [53] R
Single center
63 ICU and
general
ward
69% 59 8 days 9% 27% All patients assessed for use
of prophylaxis with
weight-adjusted dalteparin
Leonard-Lorant et al.
[54]
R
Double
center
106 ICU and
general
ward
66% 63.5 NR 30% NR Anticoagulant not specified.
In PE + group, 78% were
on prophylactic doses and
6% were on therapeutic
doses.
Grillet et al. [55] R
Single center
100 ICU and
general
ward
70% 66 NR 23% NR NR
Bompard et al. [58] R
Double
center
135 ICU and
general
ward
70% 64 5 days 23.7% 50% ICU
18% GW
All patients received standard
dose of prophylaxis (Enox
4000 daily in GW, twice
daily in obese and ICU
patients)
Galeano-Valle et al.
[90]
P
Single center
24 General
ward
58% 64.3 14 days 6.5% NR All patients received
standard dose of
prophylaxis (enoxaparin
4000 UI daily or
bemiparin 3500 UI daily)
Hippensteel et al. [91] R
Single center
91 ICU 58% 55 NR 5.5% 26.1% 54.3% of patients received
therapeutic anticoagulation
P, prospective; R, retrospective; ICU, intensive care unit; NR, not reported; LMWH, low molecular weight heparin; UFH, unfractionated heparin
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thrombotic and bleeding risk. Finally, in hospitalized COVID-
19 patients with verified VTE, the aforementioned consensus
statements stimulate the use of full therapeutic doses of anti-
thrombotic drugs (LWMH as most preferred, followed by
unfractionated heparin) in all patients without contraindica-
tions, with carefully monitoring renal function, thrombocyte
count, and concomitant medications. Antithrombotic prophy-
lactic and therapeutic regimens in various clinical scenarios as
recommended by relevant societies are shown in Table 3.
A treatment rationale for recommendations elaborated
above is also partially based on the reported survival benefits,
if the anticoagulation regimen is initiated in these patients. Of
note, one study showed that treatment with prophylactic doses
of LMWHwas associated with lower 28-day mortality among
patients with severe COVID-19 that had sepsis-induced coag-
ulopathy score ≥ 4 or D-dimers > 6-fold of an upper limit of
normal, compared with LMWH non-users [109]. However,
the crude difference between the unselected group of patients
that received LMWH vs. non-receivers in 28-day mortality
endpoint was not significantly different. Similarly, another
study found the significantly increased probability of survival
in 2773 hospitalized COVID-19 patients if systemic
anticoagulation was initiated, compared with if it was not,
especially among patients that requiredmechanical ventilation
[110]. One of the putative explanations for the beneficial
effect of heparin and its derivatives in COVID-19 is based
on the fact that heparins exhibit pleiotropic actions beyond
anticoagulation, including direct anti-inflammatory action, as
demonstrated by the decreased levels of inflammatory bio-
markers in pre-clinical and clinical settings [111, 112].
Given that the severe inflammatory response in COVID-19
is the principal driver of coagulopathy, the concept of using
heparin and its derivatives seems clinically validated as they
likely blunt both thrombotic and inflammation pathways, thus
improving outcomes in these patients.
Recommendations for Clinicians
COVID-19 caused by SARS-CoV-2, at the severest stages
might be considered as a thromboinflammatory disease rather
than an infection. In fact, the presence of microthrombotic
pulmonary disease led to the suspicion that pulmonary
macro- or microembolism could play a role in the pathophys-
iology and clinical deterioration of COVID-19 patients [1,
113]. The diagnosis of PE or MicroCLOTS may be challeng-
ing, because there are some overlapping features between pul-
monary embolism and severe COVID-19 disease, such as
dyspnoea, high levels of D-dimers, right ventricle with systol-
ic dysfunction or enlargement, and ARDS. Most of the
Table 2 Laboratory tests
reflecting hemostasis in patients
with COVID-19 associated
coagulopathy
Laboratory variable COMMENTS
Standard coagulation and platelet panel
D-dimer ↑↑↑ Markedly elevated
3- to 4-fold elevation associated with high mortality
FDPs ↑↑ Elevated
Fibrinogen ↑↑
(↓)
Elevated
Decreasing trend if patient’s condition progresses towards
consumptive coagulopathy phenotype (e.g., DIC)
aPTT ←→ (↑) In normal range OR slightly prolonged
PT ←→ (↑) In normal range OR slightly prolonged
Platelet count ←→ (↓) (↑) Near normal OR mildly decreased
Ranging from 100–150 × 109 cells/L in 70–95% patients with
severe COVID-19, platelet count < 100 × 109 cell/L was detected
in about 5% of severe COVID-19 patients. Could be slightly
increased based on limited data from small cohorts
Advanced rheological parameters
Plasma viscosity ↑↑ Increased 2-fold, on average
Factor VIII activity ↑ Increased
von Willebrand factor ↑ Increased
Antithrombin activitiy (↓) Modestly decreased
Free protein S (↓) Modestly decreased
Protein C (↑) Modestly increased
aPTT, activated partial thromboplastin time; FDPs, fibrin degradation products; PT, prothrombin time. ←→
indicates normal range. (↑) and (↓) denote modest increase or decrease, respectively; ↑ and ↓, slightly increase
or decrease, respectively; ↓↓ and ↓↓, considerably increase or decrease, respectively; and ↑↑↑ and ↓↓↓ strongly
increase or decrease, respectively
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Table 3 Antithrombotic prophylaxis and treatment regimens in various settings of COVID-19 infection according to international societies
Society/Document (PubMed ID
number)
Antithrombotic agent and dosage Population Duration of treatment
COVID-19 patients WITHOUT diagnosis of VTE
International Society of
Thrombosis and Haemostasis
(ISTH) (PMID: 32338827)
LMWH
In standard VTE prophylactic dose, in
the absence of contraindications*
All COVID-19 patients who require
hospitalization (including
non-critically ill patients)
During the whole duration of
hospital stay
STH – Subcommittee of
Perioperative and Critical
Thrombosis and Haemostasis of
the Scientific and
Standardization Committee
(PMID: 32459046)
LMWH (preferred agent, once daily)
OR UFH (twice or thrice daily) OR
DOACs (least preferred, due to
interference w/ immunosuppressant
and antiviral drugs), in the absence
of relevant contraindications*
All in standard VTE prophylactic
doses**
Intermediate-dose LMWH in-hospital
may be considered in severe patients
All non-ICU hospitalized
COVID-19 patients
During the whole duration of
hospital stay
Extended duration
thromboprophylaxis with LMWH
or DOAC for 2–6 weeks (14 days at
least, up to 30 days) post-discharge
in selected patients with low risk for
bleeding and key VTE risk factors
could be used****
LMWH (preferred agent, once daily)
OR UFH (twice or thrice daily)
All in standard VTE prophylactic
doses*
Intermediate-dose LMWH in-hospital
can be considered in high-risk
patients
Full-dose heparin treatment is
not recommended
All ICU hospitalized COVID-19
patients
During the whole duration of
hospital stay
Extended duration
thromboprophylaxis with LMWH
or DOAC for 2–6 weeks (14 days at
least, up to 30 days) post-discharge
in selected patients with low risk for
bleeding and key VTE risk factors
could be used****
Italian Society on Thrombosis and
Haemostasis (SISET) (PMID:
32281926)
LMWH OR UFH OR fondaparinux
All in standard VTE prophylactic dose,
in the absence of contraindications*
Intermediate-dose LMWH in-hospital
(enoxaparin 4000 IU
subcutaneously, twice daily) could
be considered on an individual basis
in patients with multiple risk factors
for VTE
Full-dose heparin treatment is
not recommended
All hospitalized COVID-19 patients During the whole duration of the
hospital stay
Maintained at home for 7–14 days
post-discharge in case of
pre-existing or persisting VTE risk
factors
ISTH, North American
Thrombosis Forum (NATF),
European Society of Vascular
Medicine (ESVM), International
Union of Angiology (IUA),
European Society of Cardiology
(ESC) Working Group on the
Pulmonary Circulation and
Right Ventricular Function
(PMID: 32311448)
LMWH, once daily, preferred agent
OR
UFH, twice daily
Both in standard VTE prophylactic
dose, in the absence of
contraindications*
Mechanical VTE prophylaxis in
patients with contraindications in
immobilized patients
Prophylactic anticoagulation is the
only fully recommended modality
Intermediate-dose LMWH in-hospital
could be an option in select patients
(minority of the panel support this
option)
Full-dose heparin treatment is not
recommended
Hospitalized patients with
COVID-19 who have: respiratory
failure or comorbidities such as
active malignancy or heart failure,
are bedridden or requiring intensive
care
During the whole duration of
hospital stay
Extended duration
thromboprophylaxis with LMWH
or DOAC for up to 45 days among
patients with high VTE risk and low
risk of bleeding****
COVID-19 patients WITH confirmed diagnosis of VTE
International Society of
Thrombosis and Haemostasis
(ISTH) (PMID: 32338827)
Not discussed N/A N/A
ISTH – Subcommittee of
Perioperative and Critical
Thrombosis and Haemostasis of
the Scientific and
Standardization Committee
(PMID: 32459046)
LMWH
(inpatient setting; a change from
treatment-dose DOACs or VKAs to
in-hospital LMWH should be
considered in critical care patients
wtih relevant concomitant
medications, based on renal function
and thrombocyte count)
All hospitalized COVID-19 patients
with established VTE
Duration of anticoagulation
treatment should be at least 3
months
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inpatients with COVID-19 should receive at least prophylactic
anticoagulation in the absence of contraindication, particularly
those at ICU, due to high reported incidence of VTE in this
context [8, 89]. There are some observational studies suggest-
ing that heparin improves the disease prognosis when the in-
dication bias would suggest a worse prognosis (i.e., patients
that received anticoagulation probably had an indication that
could worsen the prognosis but the data suggests otherwise)
[89, 109]. As there is no guidance for deciding the intensity of
anticoagulation (prophylactic, intermediate, or therapeutic),
the decision-making process should be made in individual-
case basis, while studies are ongoing (NCT04377997,
NCT04362085, NCT04367831). The suspicion of PE should
be based in clinical grounds (unexplained chest pain, unex-
plained RV dysfunction, unilateral lower limb swelling) and
not only in biomarkers such as D-dimers. It is known that D-
Table 3 (continued)
Society/Document (PubMed ID
number)
Antithrombotic agent and dosage Population Duration of treatment
DOACs
(post-hospital discharge setting)
Standard VTE therapeutic doses in the
absence of contraindications*
Prophylactic or intermediate-dose to
treatment-dose regimen might be
considered in patients without
verified VTE but with worsening
pulmonary status or ARDS
Italian Society on Thrombosis and
Haemostasis (SISET) (PMID:
32281926)
LMWH
OR
UFH
OR
DOACs
Standard VTE therapeutic doses in the
absence of contraindications*
All hospitalized COVID-19 patients
with established VTE
Duration of treatment in this
scenario should be according to
established classic guidelines for
therapeutic anticoagulation of
established VTE
In patients requiring therapeutic doses
of LMWH or DOACs, a careful
monitoring of renal function with
anti-factor Xa or plasma DOAC
levels assays should be instituted
VKAs and DOACS significantly
interfere with concomitant antiviral
treatment and individualized
risk/benefit approach should be
applied for every patient
ISTH, North American
Thrombosis Forum (NATF),
European Society of Vascular
Medicine (ESVM), International
Union of Angiology (IUA),
European Society of Cardiology
(ESC) Working Group on the
Pulmonary Circulation and
Right Ventricular Function
(PMID: 32311448)
UFH, parenteral (preferred in critical
patients that might undergo
procedures)
OR
LMWH, subcutaneous (preferred in
patients unlikely to undergo
procedures)
DOACs OR LMWH
(preferred as post-discharge therapy
due to reduced need for contact with
healthcare workers required for INR
monitoring of VKAs)
All in standard VTE therapeutic doses,
in the absence of contraindications*
Mechanical VTE prophylaxis in
patients with contraindications in
immobilized patients
Hospitalized patients with
COVID-19 with established VTE
Duration of treatment in this
scenario should be according to
established classic guidelines for
therapeutic anticoagulation of
established VTE
ARDS, acute respiratory distress syndrome; DOACs, direct oral anticoagulants; INR, international normalized ratio; LMWH, low molecular weight
heparin; UFH-unfractionated heparin; VKA, vitamin K antagonist; VTE, venous thromboembolism
*Active bleeding, thrombocyte count < 25 × 109 /L, severe renal impairment (close monitoring required)
**Treatment should bemodified individually according to patient’s bodyweight, severity of thrombocytopenia (25–50 × 109 cells/L) or worsening renal
function; intermittent pneumatic compression devices might be used in patients in whom anticoagulant therapy is contraindicated
***Obese patients (body mass index ≥ 30) should be considered for the 50% increase in the dose of thromboprophylaxis; multimodal prophylaxis with
mechanical methods such as intermittent pneumonic compression devices should be considered
****High-risk factors defined as advanced age, stay in the ICU, cancer, a prior history of VTE, thrombophilia, severe immobility, elevated D-dimer
levels (> 2 times of upper normal range), and an IMPROVE VTE score of 4 or more
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dimers are frequently high in COVID-19 inpatients [62], they
are a prognosis biomarker [114], but it is not clear if they
reflect the existence of macrovascular thrombosis and/or the
need to screen systematically VTE in these patients [108].
As for myocardial injury/infarction, there are also chal-
lenges because elevated troponin levels are often seen in
COVID-19 patients, and the cause of troponin release may
be multifactorial. First, both plaque rupture can occur during
severe COVID-19 (type 1 myocardial infarction), and other
causes of troponin release can be present, including imbalance
between blood/oxygen supply and myocardial requirements,
SARS-CoV-2 myocarditis, Tako-tsubo cardiomyopathy, or
right heart failure (type 2 myocardial infarction). Patients with
ST-elevation myocardial infarction (STEMI) or high-risk non-
ST-elevation acute coronary syndrome (NSTE-ACS) should
go to the catheterization laboratory, preferably the one dedicat-
ed to COVID-19, and followed by an ICU isolation bed [115].
For patients with COVID-19 and STEMI in a non-primary PCI
center, fibrinolysis can be considered depending on the current
timings for patient transfer for a primary PCI center [115]. In
the remaining patients with COVID-19 and NSTE-ACS, phy-
sicians can opt out for optimal medical treatment alone for
clinical stabilization while further testing, or coronary angiog-
raphy should be performed after the infection is resolved [115].
Stroke in COVID-19 patients was not as common as VTE
[8]. The approach to stroke is the same as non-COVID-19
patients, pursuing the vessel recanalization when indicated
and when resources are available [116]. Ideally, these patients
should be at COVID-19 stroke units, but logistic difficulties
have been seen during the COVID-19 season [117]. In pa-
tients with severe COVID-19 disease, the development of
stroke signs and symptoms should also raise the suspicion of
paradoxical embolism through atrial septum defect.
In summary, COVID-19 is an infectious disease that leads
to a proinflammatory and prothrombotic state, resulting in
both micro- and macrovascular thrombosis, and both arterial
and venous thrombotic events. Therefore, the early recogni-
tion and vigilant monitoring of the thrombotic complication of
COVID-19 may be life-saving.
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